Brief: GC Pharma Receives Japan Approval For Hunterase ICV Injection 15 Mg As A Treatment For Mucopolysaccharidosis Type II
22/01/2021 14:14
Jan 22 (Reuters) - GC Pharma:
* GC PHARMA - RECEIVED JAPAN MANUFACTURING AND MARKETING
APPROVAL
FOR HUNTERASE ICV INJECTION 15 MG AS A TREATMENT FOR
MUCOPOLYSACCHARIDOSIS TYPE II
Source text for Eikon: ID:nBw5cWYQya
Further company coverage: 006280.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GC Biopharma
See all newsBrief: Gc Biopharma Q2 Operating. Profit 1.7 Billion Won, Down 93.8% Y/Y
Brief: Gc Biopharma Corp 006280.Ks - Q1 Operating. Profit 11.7 Billion Won, Up 46% Y/Y
Brief: Green Cross Corp Q3 Operating Profit 29.2 Billion Won, Down 26.3% From Year Earlier
Brief: GC Biopharma gets CMO rights for shingles vaccine from Curevo Vaccine
Brief: Gc Biopharma Receives Marketing Authorization For Barycela In Vietnam